Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: Evidence and ongoing controversy

被引:14
作者
Wheler, Jennifer [1 ]
Johnson, Melissa [1 ]
Seidman, Andrew [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
D O I
10.1053/j.seminoncol.2006.08.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Results of five major randomized trials have increased our understanding of the role of aromatase inhibitors in the adjuvant setting. Two of these trials, the Anastrozole or Tamoxifen Alone or in Combination (ATAC) trial and the International Breast Cancer Study Group's BIG 1-98 trial compared an aromatase inhibitor versus tamoxifen as initial hormonal therapy. Three other trial were designed as cross-over studies; the Intergroup Exemestane Study (IES) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 8/German ARNO 95 trial compared a crossover from tamoxifen to an aromatase inhibitor versus continued tamoxifen in women who had completed 2 to 3 years of tamoxifen. The MA-17 trial compared the use of letrozole with placebo for 5 years, following 5 years of tamoxifen. Based on the results of these studies, the use of an aromatase inhibitor for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer has largely replaced the previous standard of 5 years of tamoxifen. Still unanswered, however, are questions regarding optimal sequencing, selection of aromatase inhibitor, and duration of treatment. This review will provide an overview of the major studies with an emphasis on these important questions. © 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:672 / 680
页数:9
相关论文
共 34 条
  • [1] Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
    Allard, WJ
    Matera, J
    Miller, MC
    Repollet, M
    Connelly, MC
    Rao, C
    Tibbe, AGJ
    Uhr, JW
    Terstappen, LWMM
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6897 - 6904
  • [2] [Anonymous], 2006, Cancer Facts and Figures
  • [3] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
    Boccardo, F.
    Rubagotti, A.
    Guglielmini, P.
    Fini, A.
    Paladini, G.
    Mesiti, M.
    Rinaldini, M.
    Scali, S.
    Porpiglia, M.
    Benedetto, C.
    Restuccia, N.
    Buzzi, F.
    Franchi, R.
    Massidda, B.
    Distante, V.
    Amadori, D.
    Sismondi, P.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : VII10 - VII14
  • [4] Boccardo FM, 2005, J CLIN ONCOL, V23, p10S
  • [5] Clarke M, 1998, LANCET, V351, P1451
  • [6] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    Coombes, RC
    Hall, E
    Gibson, LJ
    Paridaens, R
    Jassem, J
    Delozier, T
    Jones, SE
    Alvarez, I
    Bertelli, G
    Ortmann, O
    Coates, AS
    Bajetta, E
    Dodwell, D
    Coleman, RE
    Fallowfield, LJ
    Mickiewicz, E
    Andersen, J
    Lonning, PE
    Cocconi, G
    Stewart, A
    Stuart, N
    Snowdon, CF
    Carpentieri, M
    Massimini, G
    Bliss, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1081 - 1092
  • [7] CUZICK J, 2005, J CLIN ONCOL, V23, P658
  • [8] Diamandopoulos GT, 1996, ANTICANCER RES, V16, P1595
  • [9] Dowsett M, 1995, CLIN CANCER RES, V1, P1511
  • [10] Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study
    Dowsett, M
    Cuzick, J
    Wale, C
    Howell, T
    Houghton, J
    Baum, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7512 - 7517